Efficacy of taxol in the orpk mouse model of polycystic kidney disease.
Alkaline-Phosphatase, Animal, Antineoplastic-Agents-Phytogenic, Genes-Structural, Immunohistochemistry, Kidney, Liver, Mice, Mutation, Osmolar-Concentration, Paclitaxel, Polycystic-Kidney-Diseases, Receptor-Epidermal-Growth-Factor, SUPPORT-NON-U-S-GOVT, SUPPORT-U-S-GOVT-NON-P-H-S
see Reprint Collection (pdf)
Pediatr-Nephrol 1997 Dec; 11(6):728-33.
Polycystic kidney disease (PKD) a is common disease in the human population that can lead to renal failure and death. Taxol has recently been reported to be of therapeutic benefit in the cpk mouse model of PKD. To determine whether these results also apply to other models of PKD, we studied the effects of taxol treatment on the development of renal cysts and biliary hyperplasia/dysplasia/fibrosis in the orpk mouse mutant, a unique murine model for human autosomal recessive PKD. We report no significant differences between the treatment and control groups with respect to weight gain, survival, urine to serum osmolality ratio, and serum concentration of liver enzymes. Moreover, renal cystic development was not affected by taxol treatment in the orpk mutant animals. This was confirmed by lectin staining and morphometric analysis of the renal cysts, which indicated no significant differences between treatment groups. Therefore, while taxol has a positive effect on the cystic kidney disease in cpk mutant mice, this effect is not applicable to all forms of PKD.
Efficacy of taxol in the orpk mouse model of polycystic kidney disease. Pediatr-Nephrol 1997 Dec; 11(6):728-33.